TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease

International Immunopharmacology
Xu-Dong ZhaoYan Li

Abstract

To evaluate the effects of Toll-like receptor 4 (TLR4) signaling on the activation of the transcription factor activator protein-1 (AP-1) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease (PD). The following groups were evaluated: normal saline (NS)-treated WT mice, NS-treated TLR4-knockout (KO) mice, MPTP-treated WT mice, and MPTP-treated TLR4-KO mice. After establishing the mouse model, behavioral changes were evaluated. AP-1 expression was detected by RT-PCR, Western blotting, immunohistochemistry and immunofluorescence staining. Compared to MPTP-treated WT mice, significantly reduced dyskinesia was observed in MPTP-treated TLR4-KO mice. AP-1 mRNA and protein levels were significantly up-regulated in the substantia nigras (SNs) of MPTP-treated WT mice relative to NS-treated mice (P<0.01); these levels were significantly reduced in MPTP-treated TLR4-KO mice relative to MPTP-treated WT mice (P<0.01). Immunohistochemical staining demonstrated that AP-1 was distributed throughout the SN in MPTP-treated mice, and immunofluorescence further showed that AP-1 was expressed in TH-positive neuronal cells and GFAP-positive astrocytes. In addition, immunofluorescence revealed that AP-1 e...Continue Reading

References

Apr 1, 1997·Current Opinion in Cell Biology·M KarinE Zandi
Jun 13, 2001·Oncogene·F Mechta-GrigoriouM Yaniv
Jun 13, 2001·Oncogene·W JochumE F Wagner
May 11, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Rajappa S KenchappaVijayalakshmi Ravindranath
Nov 27, 2004·Journal of Cell Science·Jochen HessMarina Schorpp-Kistner
Nov 22, 2005·Free Radical Biology & Medicine·Shuling WuReinhard Gessner
May 24, 2006·Progress in Neurobiology·Gennadij Raivich, Axel Behrens
Jun 9, 2006·In Vitro Cellular & Developmental Biology. Animal·Shubhashish SarkarGovindarajan T Ramesh
Nov 30, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Patrick L McGeer, Edith G McGeer
Mar 20, 2009·Lancet Neurology·Etienne C Hirsch, Stéphane Hunot
Apr 10, 2012·CNS & Neurological Disorders Drug Targets·Yanzhen ZhuYanjun Zeng
Jul 4, 2012·Experimental Neurology·Melanie B WatsonMarie-Françoise Chesselet
Mar 7, 2013·Scientific Reports·Carmen NoelkerAndreas Hartmann
Jan 2, 2014·Journal of Neural Transmission·Giulia AmbrosiFabio Blandini
Feb 18, 2014·Journal of Neuroimmunology·Teresa TrottaMaria Antonietta Panaro
Jun 3, 2014·Journal of Neuroinflammation·Carmen NoelkerAndreas Hartmann
May 30, 2015·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Fa-Xiang WangHui Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.